Working... Menu

Safety and Performance of the Journey™ II UNI Unicompartmental Knee System (JII-Uni)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03768128
Recruitment Status : Recruiting
First Posted : December 7, 2018
Last Update Posted : December 7, 2018
Information provided by (Responsible Party):
Smith & Nephew, Inc.

Brief Summary:
This clinical study will evaluate the early to midterm safety and performance of the JOURNEY™ II UNI UKS in patients with non-inflammatory degenerative joint disease of the knee requiring lateral or medial knee compartment replacement. Clinical, radiographic, health economic and safety outcomes will be evaluated.

Condition or disease Intervention/treatment
Non-inflammatory Degenerative Joint Disease (NIDJD) of the Knee Device: Journey™ II UNI Unicompartmental Knee System

Detailed Description:
To assess the safety and performance of the JOURNEY™ II UNI UKS in patients with unicompartmental degeneration of the knee by demonstrating non-inferiority of the cumulative percent implant survival in subjects with the JOURNEY™ II UNI UKS implanted, compared to a literature reference rate of 91.7% (AOA annual report 2015)12 at 5 years.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 147 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: A Prospective, Multicenter Post-Market Clinical Follow-up Study to Evaluate the Safety and Performance of the Journey™ II UNI Unicompartmental Knee System
Actual Study Start Date : August 10, 2018
Estimated Primary Completion Date : May 1, 2025
Estimated Study Completion Date : May 1, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Joint Disorders

Intervention Details:
  • Device: Journey™ II UNI Unicompartmental Knee System

    Journey™ II UNI UKS is a CE Marked medical device. The device has been designed to treat both medial and lateral unicompartmental disease.

    It is a comprehensive system designed to allow surgeons to perform UKA. It is comprised of the following anatomic components: Oxidized zirconium femoral components Titanium tibial components with a grit-blasted surface Polyethylene tibial insert components The device is asymmetric and is available in oxidized zirconium to reduce wear and increase implant longevity.

Primary Outcome Measures :
  1. Implant survival 5 years postoperatively [ Time Frame: 5 years ]

Secondary Outcome Measures :
  1. Device-related adverse events [ Time Frame: 5 year ]
    All AEs will be collected and reported

  2. Radiographic assessments [ Time Frame: 5 year ]
    To assess changes in implant fixation and bone integrity, an evaluation will be performed based upon comparison of Antero posterior and Lateral radiographs over multiple time-points. Radiographs will be also evaluated for radiolucencies, osteolysis, implant positioning, implant migration, implant loosening, periprosthetic fracture, wear of the articulating surfaces of replacement components

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
JOURNEY™ II UNI Unicompartmental Knee System (UKS) in patients with non-inflammatory degenerative joint disease (NIDJD) of the knee requiring either medial or lateral compartment knee replacement.

Inclusion Criteria:

  • Subjects must meet all of the following criteria for inclusion in the study.

    1. Unicompartmental, NIDJD, including OA, traumatic arthritis, or avascular necrosis.
    2. Eighteen (18) years of age or older at the time of surgery.
    3. Skeletally mature in the judgement of the PI.
    4. Has met an acceptable preoperative medical clearance and is free of (or acceptably managed) cardiac, pulmonary, hematological, infection, or other conditions that would pose an excessive operative risk.
    5. Willing and able to participate in required follow-up visits at the investigational site and to complete study procedures and questionnaires.
    6. Consented to participate in the study by signing the EC-approved ICF.

      Exclusion Criteria:

  • Subjects meeting any of the following criteria must be excluded from participation in the study.

    1. Correction of functional deformity.
    2. Revision procedures where other treatments or devices have failed.
    3. Treatment of fractures that are unmanageable using other techniques.
    4. Inadequate bone stock to support the device which would make the procedure unjustifiable, including but not limited to severe osteopenia/osteoporosis or family history of severe osteoporosis/osteopenia.
    5. Body Mass Index (BMI) > 40.
    6. Collateral ligament insufficiency.
    7. Active infection, treated or untreated, systemic or at the site of the planned surgery or previous intra-articular infections.
    8. Incomplete or deficient soft tissue surrounding the knee.
    9. Conditions that may interfere with the UKA survival or outcome, including but not limited to Paget's disease, Charcot disease, vascular insufficiency, muscular atrophy, uncontrolled diabetes, renal insufficiency or neuromuscular disease.
    10. Diagnosis of an immunosuppressive disorder.
    11. Known allergy to study device or one or more of its components.
    12. Pregnant or planning to become pregnant during the course of the study.
    13. Subject, in the opinion of the PI, has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03768128

Layout table for location contacts
Contact: Marie-Christine Mallaroni, CSM +33 (0)6 77 64 03 41

Layout table for location information
United States, Illinois
Midwest Ortho at Rush Not yet recruiting
Chicago, Illinois, United States, 60612
Contact    312-432-2429   
Principal Investigator: Tad Gerlinger, MD         
Poliambulanza Institute Hospital Foundation Not yet recruiting
Brescia, Italy, 25124
Contact    0303515718   
Principal Investigator: Flavio Terragnoli         
Istituto Clinico Villa Aprica Not yet recruiting
Como, Italy, 22100
Contact    +39 335269769   
Principal Investigator: Corrado Bait         
Capitanio Hospital Not yet recruiting
Milano, Italy, 20122
Contact    +39 338 280 38 79   
Principal Investigator: Augusto Palermo         
University Hospital of Modena Not yet recruiting
Modena, Italy, 41125
Principal Investigator: Andrea Ensini         
Zeromski Hospital Not yet recruiting
Kraków, Poland
Contact    503 198 460   
Principal Investigator: Julian Dutka         
Hospital Miejski Zabrze Recruiting
Zabrze, Poland
Contact    +48601235093   
Principal Investigator: Marek Hawranek         
Sponsors and Collaborators
Smith & Nephew, Inc.
Layout table for investigator information
Study Chair: Beate Hansen, VP, PhD Vice President, Global Clinical Strategy

Layout table for additonal information
Responsible Party: Smith & Nephew, Inc. Identifier: NCT03768128     History of Changes
Other Study ID Numbers: 16-4049-12
First Posted: December 7, 2018    Key Record Dates
Last Update Posted: December 7, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases